According to the National Center for Advancing Translational Sciences (NCATS), research development faces many hurdles; the complexity in diagnosing rare diseases, widely dispersed patients and scientific experts, and high economic risk in developing a therapy that would serve a relatively small number of patients.
At KrabbeConnect, we will breakdown these research hurdles by bringing patients to the forefront of science. In this section, we equip you with the experts in Krabbe research, share scientific advances, and act as an intermediary for clinical trials. KrabbeConnect won’t focus on the rarity of the disease instead, we will focus on creating a cohesive network that will quickly resolve major challenges, enhance disease management, and build a portfolio of viable therapies.
Dr. Dieterich Matern, Co-Director of Mayo Clinic’s Biochemical Genetics and Genomics Lab was recently honored with the Sue Rosenau Legacy Award by The Legacy of Angels Foundation for his work in newborn screening. Learn More.